Similar articles

• Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

  Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S. Chakraverty R, et al. Blood. 2002 Feb 1;99(3):1071-8. doi: 10.1182/blood.v99.3.1071. Blood. 2002. PMID: 11807015 Clinical Trial.
• CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath.

  Bainton RD, Byrne JL, Davy BJ, Russell NH. Bainton RD, et al. Blood. 2002 Nov 15;100(10):3843-4. doi: 10.1182/blood-2002-08-2398. Blood. 2002. PMID: 12411329 No abstract available.
• Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).

  Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE, Bollard CM. Myers GD, et al. Bone Marrow Transplant. 2005 Dec;36(11):1001-8. doi: 10.1038/sj.bmt.1705164. Bone Marrow Transplant. 2005. PMID: 16184180
• Non-myeloablative transplantation.

  Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA. Maloney DG, et al. Hematology Am Soc Hematol Educ Program. 2002:392-421. doi: 10.1182/asheducation-2002.1.392. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446434 Review.
• Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.

  Tam CS, Khouri IF. Tam CS, et al. Leuk Lymphoma. 2009 Aug;50(8):1239-48. doi: 10.1080/10428190903026518. Leuk Lymphoma. 2009. PMID: 19562639 Review.